安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Plerixafor - Wikipedia
Plerixafor, sold under the brand name Mozobil, is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream The stem cells are then extracted from the blood and transplanted back to the patient
- Plerixafor Uses, Side Effects Warnings - Drugs. com
Plerixafor is used in people with non-Hodgkin's lymphoma or multiple myeloma Plerixafor helps your bone marrow release stem cells into your bloodstream so they can be collected and transplanted back into your body
- Stem Cell Mobilizer Injection | Mozobil® (plerixafor) injection . . .
Mozobil (plerixafor) injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM)
- MOZOBIL (plerixafor) Injection, Solution for subcutaneous use
Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α) SDF-1α and CXCR4 are recognized to play a role in the
- Plerixafor (subcutaneous route) - Side effects uses
Plerixafor injection is used in combination with filgrastim to mobilize hematopoietic stem cells (HSC) for collection and transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) This medicine is to be given only by or under the direct supervision of your doctor
- Plerixafor - NCI - National Cancer Institute
Plerixafor helps move stem cells from the bone marrow to the bloodstream so that they can be collected, stored, and then given back to the patient in autologous stem cell transplantation Plerixafor is also being studied in the treatment of other types of cancer
- Physiology and Pharmacology of Plerixafor - PMC
Plerixafor consists of two cyclam rings with a phenylenebis (methylene) linker It inhibits CXCL12 binding to CXCR4 and subsequent downstream events including chemotaxis The molecular interactions of plerixafor have been defined indicating a unique binding mode to CXCR4
- MOZOBIL® (plerixafor) injection, for subcutaneous use . . . - Sanofi
Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM)
|
|
|